Industry: Healthcare

Navigating Cancer, the Leader in Oncology Patient Relationship Management, Receives $26 Million in Oversubscribed New Funding

Leave a comment



SEATTLE (PRWEB)

Navigating Cancer (NC), the leader in enabling personalized cancer care with its comprehensive oncology patient relationship management solution, announced today that it has received $26 million in Series D growth equity funding in an over-subscribed round led by the Merck Global Health Innovation Fund (GHIF) and TT Capital Partners (TTCP). The company’s end-to-end software platform, adopted by more than 1,700 cancer care providers domestically, uniquely connects providers and their patients throughout the care cycle.

Other investors in the round include BrightEdge, the American Cancer Society’s newly formed philanthropic venture fund; LabCorp®; ORIX Growth Capital; and Rustic Canyon Partners.

The funding will enable NC to accelerate innovation of its Patient Relationship Management (PRM) platform, including delivery of a more robust mobile experience for oncology patients and the development of NC’s AI-based population care capabilities. With NC’s platform, oncology practices are able to increase patient engagement, create a more responsive experience for cancer patients, and ultimately improve overall cancer care.

Forty Percent Growth Predicted in 2019

For 2019, Navigating Cancer is on pace to grow its oncology customer base by 40 percent. Accelerating adoption of NC’s unique platform is enabling more practices to succeed in delivering value-based care, a model that pays hospitals and physicians based on patient outcomes as opposed to fixed fees based on the service provided.

Navigating Cancer’s PRM platform helps providers manage patient interactions, improve the patient experience, and deliver value-based care more effectively – increasing the flow of communications between in-office visits, which, in turn, boosts patient engagement in their own care. NC’s platform also helps providers contain escalating costs. According to a study published in the Journal of Oncology Practice, two community cancer centers utilizing NC’s PRM platform generated significant cost savings due to better symptom management, while reducing emergency room visits by seven percent.

“This investment from these leading healthcare organizations really affirms the work that Navigating Cancer is doing to improve patient care and the success we’re seeing in helping oncology providers make the shift to value,” said Bill Bunker, the CEO of Navigating Cancer. “I’m excited about the innovations we’re making in areas like patient-reported outcomes and population care and the potential they have to further improve patient outcomes and satisfaction.”

“Oncologists must care for patients in an extremely complex regulatory and reimbursement environment, while managing a rapidly expanding number of therapy choices and effects across indications,” said David M. Rubin, Ph.D., Managing Director of Merck GHIF. “We’re delighted to continue our investment in this comprehensive patient care platform.”

Specifically, patients using the PRM platform can send messages to their doctor, receive reminders to take their medications, and report symptoms via a mobile app. Care providers, meanwhile, can triage patient needs; assess and manage symptoms and side effects; and streamline communications and care coordination for quicker responses.

Going forward, innovation in the PRM platform will incorporate artificial intelligence to support the assessment of patients at risk for various issues and identify proactive interventions to help improve care.

“More and more oncology practices are picking up the NC oncology platform because it’s a superb example of the heightened effectiveness created by leveraging 21st century technology in the practice of medicine,” said Bob Crutchfield, managing director of BrightEdge, the philanthropic impact fund of the American Cancer Society.

“As the dynamics of how providers, patients, and caregivers interact with one another continue to change in healthcare, Navigating Cancer’s platform represents a powerful example of technology enhancing the delivery of care and improving the overall healthcare experience,” said Tim Scallen, Principal at TT Capital Partners. “We look forward to collaborating with the management team to further extend Navigating Cancer’s platform reach and enhance the benefits it delivers to all cancer patients and providers.”

About Navigating Cancer

Navigating Cancer is the leading Patient Relationship Management technology and solutions company focused on improving the patient experience, delivering more effective care management and enabling oncology care innovation. With over 1,700 providers adopting the Navigating Care platform, it is the most broadly deployed patient management solution in oncology. The company’s products combine clinical workflows, oncology content and data insights to empower personalized care for cancer patients inside and outside of the clinic. For more information, please visit http://www.navigatingcancer.com or follow Navigating Cancer on Twitter @navcancer.

About TT Capital Partners

TT Capital Partners (TTCP) is a healthcare investor, collaborating with healthcare technology and services companies that have the potential to become market leaders. Leveraging the insights garnered from a unique knowledge-based platform, TTCP has invested in some of the most innovative, high-growth healthcare businesses. TTCP is part of the TripleTree healthcare merchant bank. For more information, visit TTCapitalPartners.com.

About BrightEdge

BrightEdge is the American Cancer Society’s donor-funded, philanthropic impact fund. The fund is led by a board comprised of the Society’s leaders and a management team with expertise in investment and venture capital. BrightEdge operates under a charitable fund model that invests in for-profit companies developing novel cancer-focused therapies and technologies. The fund relies on the expertise of the Society’s medical and science professionals to evaluate the mission value of its investments. The fund’s goal is to accelerate delivery of promising cancer-related solutions through capital investment, market awareness and a shared commitment to eradicate cancer. https://brightedgefund.org/.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenues of more than $11 billion in 2018. To learn more about LabCorp, visit http://www.LabCorp.com, and to learn more about Covance Drug Development, visit http://www.Covance.com.

Business: Insurance

What are the Main Benefits of Crash Avoidance Technology

Leave a comment


News Image

“Investing in crash-avoidance technology is money well-spent. Nothing is more important than your life,” said Russell Rabichev, Marketing Director of Internet Marketing Company.


LOS ANGELES (PRWEB)

Compare-autoinsurance.org has released a new blog post that presents the benefits of crash-avoidance technology and how it can help drivers lower car insurance premiums.

For more info and free auto insurance quotes, visit https://compare-autoinsurance.org/how-crash-avoidance-technology-works-and-its-benefits/.

A high number of cars translates into a high likelihood of being involved in an accident. To decrease the odds, more and more cars are equipped with performant sensors and cameras. Crash-avoidance technology informs the driver when a car, obstacle or pedestrian gets too close. This technology will reduce the number of accidents and will save lives.

The most popular crash-avoidance systems include:

  • Frontal collision prevention. These systems are complex, comprising several sensors, radars and cameras (including night-vision cameras) and will detect nearby cars and obstacles. Some systems will automatically brake in order to prevent a collision.

  • Lane departure warning is also an extremely useful system. If the driver passes the lane lines, he will receive audio warnings. Just like in the case of frontal collision prevention, the system may take over control and guide the car to the correct lane.

  • Blind spot detectors are probably some of the most popular systems. Sensors will detect cars placed in the blind spots and will emit various luminous signals (usually on dashboard, rear camera or mirror).

  • Adaptive cruise control will measure the distance between the driver’s car and the car in front and calculate its speed. In order to maintain a safe driving distance, the system will adjust the speed of the car.


For more information and free online quotes, please visit http://compare-autoinsurance.org.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

Share article on social media or email:

Business: Executives

Morphisec Appoints Eric Dougherty as Chief Revenue Officer

Leave a comment


Morphisec

Morphisec is uniquely positioned to capitalize on this change in enterprise security strategies, and Eric’s extensive experience working with growth companies, as well as his track record in building successful global sales teams, makes him an ideal appointment to our leadership team.


BE’ER SHEVA, Israel and BOSTON (PRWEB)

Morphisec, the leader in Moving Target Defense, today announced it has appointed Eric Dougherty to Chief Revenue Officer (CRO). In this role, Dougherty will lead all customer acquisition, expansion and retention efforts for the company as it accelerates its growth in global markets. Morphisec has doubled the global install base of its Unified Threat Prevention platform in just over eight months to more than four million endpoints as demand skyrockets for its advanced threat protection as the ideal companion to Microsoft’s built-in Windows Defender Antivirus (AV) in more efficient enterprise security stacks.

“We’re excited to have Eric join our team as a paradigm shift is occurring in the cybersecurity market where enterprises are moving to a prevention-first model against advanced attacks as the limitations and burdens of EDR solutions becomes more apparent,” said Ronen Yehoshua, Morphisec’s CEO. “Morphisec is uniquely positioned to capitalize on this change in enterprise security strategies, and Eric’s extensive experience working with growth companies, as well as his track record in building successful global sales teams, makes him an ideal appointment to our leadership team.”

Dougherty has over two decades of experience working with growth companies in the cybersecurity, data protection, and enterprise infrastructure markets. He most recently served as VP of Americas Sales for EnterpriseDB. Prior to that, he was the SVP of worldwide sales for Unitrends. Within that role, Dougherty built the sales and channel strategy for Unitrends that resulted in a 400% growth and hitting a $100M run rate in less than four years. During his previous stints at Rapid7 and Acronis, Dougherty built go-to-market channel strategies and sales teams that led to partner expansion, customer wins, and sales growth. Dougherty also spent more than six years at Axis Communications, where his sales success as General Manager for the Americas contributed to a successful IPO in 2000.

“As enterprises move to Windows 10 they are realizing the time has come to step away from legacy antivirus tools, as well as the cost and time burden of EDR solutions,” added Dougherty. “Morphisec is reaping the benefits of the enterprise adoption of Windows Defender AV as organizations of all sizes divest themselves from redundant tools and reallocate budgets to their biggest current need — advanced threat protection. I look forward to expanding Morphisec’s sales team to meet this global demand and assisting our customers with implementing preventative endpoint security within a simpler operational environment that improves their ROI.”

About Morphisec

Morphisec delivers an entirely new level of innovation with its Moving Target Defense-powered Unified Threat Prevention Platform – placing defenders in a prevent-first posture against the most advanced threats to the enterprise, including APTs, zero-days, ransomware, evasive fileless attacks and web-borne exploits. Morphisec provides a crucial, small-footprint memory-defense layer that easily deploys into a company’s existing security infrastructure to form a simple, highly effective, cost-efficient prevention stack that is truly disruptive to today’s existing cybersecurity model.

Share article on social media or email:

Health

VISTAAR Announces Addition of “ADVISORY Playbooks” to it’s Regulatory & Clinical Intelligence Platform

Leave a comment


VISTAAR-Regulatory-Clinical-Intelligence

VISTAAR

Access Regulatory Guidance Documents with One Click


PRINCETON, N.J. (PRWEB)

VISTAAR released ADVISORY Playbooks to help small and mid-level companies who need advisory either as a primary strategy or as re-assurance / 2nd opinion to their internal strategies they formed for developing or launching new products or expanding to new countries.

Lot of users when going into new markets, or planning to change their product elements and want to know the impact, introducing new product or to support their R&D teams, have ideas and thoughts but may not have a question clearly framed. VISTAAR while driving initial probing questions, you can give your needs or plans and VISTAAR than by leveraging its AI engine provides you a Regulatory strategy on what is needed, options, country requirements, forms/checklists, what other companies are doing in that scenario, what other products have those situations or parameters and more.

When someone cannot afford a senior consultant or need an initial pathway, these Playbooks can drive that process by significantly reducing the time and cost required compared to analyzing all the documents and information manually.

Try for a month FREE to test it for yourself. VISTAAR’s AI enabled Intelligence helps navigate today’s complex product development and regulatory landscape Better, Faster and Cheaper than any other regulatory and clinical intelligence platform. Visit http://www.vistaar.ai

Share article on social media or email:

Science: Biology

Study indicates early infusion of mononuclear cells could aid in recovery from stroke

Leave a comment


https://www.prweb.com/

Lead investigator on the study, Sean Savitz, M.D.


DURHAM, N.C. (PRWEB)

Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients. The information provided by the study could aid in developing new cellular therapies for this most common form of stroke — caused by a blocked artery — which affects over 13 million people each year, according to the World Health Organization.

The study in STEM CELLS is a follow up to the initial report on the first 10 patients in the trial, published in the Annals of Neurology in 2011. The STEM CELLS paper represents the total group of 25 patients.

Sean Savitz, M.D., director of the Institute for Stroke and Cerebrovascular Disease and professor of neurology at McGovern Medical School at UTHealth Houston, was lead investigator on the study. “Having found no clear evidence of harm to the initial 10 patients,” he said, “we broadened the inclusion criteria and enrolled additional patients. Our choice of cell type — bone marrow mononuclear cells (BM MNCs) – dose (10 million cells/kg), timing; route of administration; and the autologous approach was based on, and is in line with, growing evidence from animal stroke models and clinical evidence for possible treatment effects in our traumatic brain injury studies and other diseases.”

BM MNCs are attractive in regenerative medicine studies because they can be rapidly isolated; are enriched with hematopoietic, mesenchymal and endothelial progenitor cells; and permit autologous applications. Preclinical studies consistently indicate that MNCs improve outcome when administered within 72 hours of stroke onset and at least one clinical trial has shown they are not effective beyond seven days, the researchers said.

The regenerative potential of BM-derived MNCs is attributed to various mechanisms that impact stroke recovery. The cells migrate to the site of injury, release cytokines and other trophic factors, decrease proinflammatory and upregulate anti-inflammatory pathways, among other things. They also are easily amenable to autologous infusion, eliminating the need for immunosuppressive drugs.

“In contrast to the generation of autologous mesenchymal stem cells, another promising cell therapy,” added Dr. Savitz, “MNCs do not require passage in culture, which allows for testing in the early post-stroke time window.”

Each patient in the Savitz team’s study received an intravenous dose of their own BM MNCs within 72 hours after onset of their stroke. They were then followed for one year after treatment and the results compared to a control group of 185 acute ischemic stroke patients who received conventional treatment only. No definite severe adverse events related to the procedures were seen in any of the 25 patients, the research showed.

“In the light of our findings,” said Dr. Savitz, “we believe that MNCs pose no additional harm in ischemic stroke patients when given during the acute phase, doses up to 10 million cells/kg are tolerated and it is feasible to perform a BM harvest and re-infusion of MNCs for a wide range of stroke patients. Well-designed random clinical trials are needed to further assess safety and efficacy of this novel approach to enhance stroke recovery.”

“New options to treat Ischemic stroke are desperately needed,” said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. “This important clinical trial provides solid safety and feasibility data on which later trials can be built, using the patient’s own bone marrow stem/progenitor cells to potentially enhance recovery after ischemic stroke.”

The full article, “Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3080.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world’s first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.wiley.com.

Share article on social media or email:

Technology: Computer

Symphony Post Acute Network Selects Trella Health as Ally in Healthcare Technology Revolution

Leave a comment



ATLANTA (PRWEB)

Symphony Post Acute Network, a premier skilled nursing provider that operates 26 facilities across four states, announced the selection of Trella Health (formerly Excel Health) as its post-acute outcomes data and performance analytics solution.

“I was impressed with the level of insight related to market dynamics and structure that [Trella’s] simple to navigate platform delivers,” said Michael Munter, Chief Operating Officer of Symphony. “We are proud to be a leader in the healthcare technology revolution and welcome the opportunity to partner with innovative firms like Trella as our industry continues to develop, mature, and adapt to the ever-changing healthcare landscape.”

Trella Health CEO Ian Juliano echoed Munter’s sentiment, stating, “We’re thrilled to add Symphony to our growing list of skilled nursing customers. They’re a company that has truly embraced the power of data, from both a clinical and business operations standpoint- and bridging that gap to improve outcomes is the future of healthcare.”

Symphony has been experimenting with using technology to assist with clinically appropriate ways to reduce hospital readmissions, including employing a machine learning platform to assess and score incoming patients, so selecting Trella as an analytics provider was a natural solution. With access to the healthcare industry’s most current and complete data, Trella’s solutions for skilled nursing, home health, and hospice empower customers to transform their marketing and sales efforts, grow their care networks, and compare and improve quality while optimizing costs. To learn more about the Trella Health platform, please contact us at info@trellahealth.com or visit http://www.trellahealth.com and grow your business with confidence.

About Symphony Post Acute Network

Symphony Post Acute Network is one of the most innovative providers of post-acute care in the United States. They are a proud, family-focused organization that takes a proactive approach to delivering quality outcomes for the guests in their care. Symphony is committed to making every one of its locations the Provider of Choice in the community that they serve by demonstrating an unmatched ability to meet patients’ needs and offer them a consistently high level of quality care. Ten of Symphony’s facilities have been accredited by the Joint Commission for ensuring the highest standards in the industry. The four rings in the logo represent the important roles that guests, community, family, and staff play in Symphony’s approach to providing the best possible care.

About Trella Health

Trella Health provides post-acute business development leaders with the most complete picture of care activity in their service areas so they can explore new opportunities for growth. As one of only a few companies in the country deemed ‘Innovators’ under the Center for Medicare and Medicaid Service’s Virtual Research Data Center Program, Trella has access to 100% of Medicare Part A and Part B claims data. Trella analyzes 1.2 billion claims annually and presents relevant insights to nearly 10,000 users so they can build higher-performing care networks, serve more patients, and reduce the cost of care.

Share article on social media or email:

Technology: Electronics

Intrinsic ID and Guardtime Create Blockchain-based Security Architecture for Renewable Energy Trading System Supporting Rotterdam’s ‘Digital Twin’ Initiative

Leave a comment


Intrinsic ID

Intrinsic ID

We are thrilled to have worked on this project together and look forward to deepening our relationship with Intrinsic ID. New approaches, such as the combination of Instrinic ID’s PUF technologies and Guardtime’s KSI Blockchain, will become increasingly more important. – Mike Gault, CEO, Guardtime


AMSTERDAM and SUNNYVALE, Calif. (PRWEB)

Intrinsic ID, the world’s leading provider of digital authentication technology for Internet of Things security, and Guardtime, the global leader in enterprise blockchain, today announced the companies have completed their joint work on a blockchain-based security architecture for a renewable energy trading system. This distributed-ledger-based real-time energy marketplace for solar, wind and battery is in support of the city of Rotterdam’s “Digital Twin” initiative.

The companies completed presentation and demonstration of the Phase II Small Business Innovation Research (SBIR) project “Open Energy Network” to the Dutch Ministry of Economic Affairs, BlockLab and Enterprise Agency RVO, which stimulates entrepreneurs in sustainable, innovative and international business.

Rotterdam is creating a “digital twin” for the city, which will act as a platform for a new era of digital city applications. The digital twin is a smart 3D model of Rotterdam that accurately represents the streets, buildings, public spaces and other physical elements of the city. The critical nature of this marketplace demands best-in-class security, including a hardware-based root of trust powered by SRAM PUF – physical unclonable function – complemented by blockchain-based distributed ledger technology.

The project is funded under a contract awarded by the Dutch government and the city of Rotterdam, and managed by BlockLab, a subsidiary of the Port of Rotterdam. BlockLab develops use cases with alliances including engineers, developers and end users, with a focus on energy and logistics.

“We have demonstrated how Intrinsic ID’s SRAM PUF technology and Guardtime’s KSI blockchain technology create synergistically a strong solution for the renewable energy markets,” said Pim Tuyls, chief executive officer of Intrinsic ID. “It is a pleasure to have created a combined solution together with Guardtime for the City of Rotterdam to allow them to optimize energy utilization in a secure manner.”

KSI Blockchaiin is an especially efficient method for issuing and verifying signatures which accelerates the scalability of SRAM PUF.

“We are thrilled to have worked on this project together and look forward to deepening our relationship with Intrinsic ID,” said Mike Gault, chief executive officer of Guardtime. “Traditional technologies such as PKI are completely impractical in a world of 5G networks and edge computing and new approaches, such as the combination of Instrinic ID’s PUF technologies and Guardtime’s KSI Blockchain, will become increasingly more important.”

The project was prompted as an answer to a major challenge the region of Rotterdam faces, the suboptimal utilization of energy capacity. To address this, the Dutch government seeks to transform energy markets from closed and centralized to open and distributed. The metropolitan region of Rotterdam and The Hague have a combined population of 2.2 million, with 1 million homes and 128 thousand companies – including the Port of Rotterdam, the largest port in Europe.

In Phase I of the joint project by Intrinsic ID and Guardtime, a cloud-based demonstrator with connected smart meters was developed, combining the core strengths of the two companies. Intrinsic ID’s BroadKey is a proven software solution for authentication of IoT devices such as smart meters. Authenticating smart meters securely at a hardware level by means of software, identifying every member in the network, brings the necessary level of IoT device security and makes it impossible for unauthorized devices to join. Guardtime’s KSI Blockchain is used to ensure integrity and time of every event in the network – making them verifiable independently, regardless of vendors, distribution networks or service providers.

Phase II of the project goes beyond the proof of concept and is tackling the challenges of scalability and end-to-end security for this multiparty complex ecosystem of energy network. Intrinsic ID has worked on the Firmware-Over-The-Air secure updates of smart meters, allowing millions of smart meters to receive verifiable updates with the latest software and firmware libraries, system policies and network configurations. This enables managing millions of smart meters in a time-efficient and low-cost way by avoiding time-consuming manual efforts.

Intrinsic ID and Guardtime supported an extra security layer to support trustworthy communications. This allows the reading values of smart meters to arrive to a decentralized trading platform reliable and secure, without intermediate networking parties have access to them, and assuring that the smart meter cannot deny the authenticity of the measurements.

About Guardtime

Guardtime is the world’s leading enterprise blockchain company. The company was founded in Estonia in 2007, where it products are used to underpin Estonian digital society, and has since expanded with a presence in the UK, Middle East, Asia and the Americas. Example solutions that the company has built, working with industry partners, include GDPR compliance as service, physical anti-counterfeit, marine insurance data exchange, physical supply chain track and trace, digital content management, software lifecycle management, critical infrastructure protection and health-care interoperability.

About Intrinsic ID

Intrinsic ID is the world’s leading digital authentication company, providing the Internet of Things with hardware-based root-of-trust security via unclonable identities for any IoT-connected device. Based on Intrinsic ID’s patented SRAM PUF technology, the company’s security solutions can be implemented in hardware or software. Intrinsic ID security, which can be deployed at any stage of a product’s lifecycle, is used to validate payment systems, secure connectivity, authenticate sensors, and protect sensitive government and military systems. Intrinsic ID technology has been deployed in more than 150 million devices. Award recognition includes the Cyber Defense Magazine InfoSec Award, the IoT Breakthrough Award, the IoT Security Excellence Award, the Frost & Sullivan Technology Leadership Award and the EU Innovation Radar Prize. Intrinsic ID security has been proven in millions of devices certified by Common Criteria, EMVCo, Visa and multiple governments. Intrinsic ID’s mission: Authenticate EverythingTM. Visit Intrinsic ID online at http://www.Intrinsic-ID.com.

Intrinsic ID, the Intrinsic ID logo, BroadKey and “Authenticate Everything” are trademarks or registered trademarks of Intrinsic ID, B.V., and are protected by trademark laws of the United States and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective companies.

Media Contact for Guardtime

Rachel De Haan

Guardtime Global Media Relations

pr@guardtime.com

Media Contact for Intrinsic ID

Milan G. Lazich, Sr. Director Marketing

[+1] 408-933-9980

press@intrinsic-id.com

Society: Social Services

Experienced Disability Advocate Alexandria Baland Joins Pond Lehocky Disability

Leave a comment



PHILADELPHIA (PRWEB)

Pond Lehocky Stern Giordano Disability is pleased to announce that it has added Alexandria Baland as a Social Security disability associate with the nationwide advocacy group. Ms. Baland has dedicated most of her career to providing legal assistance to disabled individuals. Her knowledge and experience should be a tremendous asset in helping the group serve those with disabilities.

Before joining Pond Lehocky Disability, Ms. Baland worked as an associate at New Jersey law firm, assisting disabled children and their families with matters including guardianship and special needs trusts. She also frequently spoke to groups for parent of disabled children regarding Social Security disability, special education and other related topics.

She has also served as a staff attorney at a New Jersey non-profit that provides free legal services to indigent clients, handling Social Security, housing and other civil matters. In addition, she has worked as a document review attorney, assisting a large Philadelphia law firm in pharmaceutical injury litigation.

While attending school, Ms. Baland emphasized service to the disabled. She graduated from Syracuse University College of Law’s Disability Law and Public Policy joint degree program, earning her J.D. and a master’s degree in disability studies and receiving recognition for her pro bono work. While there, she worked as a student attorney at the school’s Disability Rights Clinic, assisting the disabled with issues including special education, accessibility and prisoners’ rights. She also served as president of the Disability Law Society.

Ms. Baland earned her bachelor’s degree in political science and Spanish from Temple University, where she was a member of the school’s Division I rowing team. She is fluent in both English and Spanish.

Pond Lehocky Disability was the result of the tremendous growth of the law firm of Pond Lehocky Stern Giordano. After becoming the largest firm of its kind and assisting more than 85,000 Americans in all 50 states and Puerto Rico, the firm’s Social Security disability department became its own advocacy group – Pond Lehocky Stern Giordano Disability. Pond Lehocky Disability has teams of experienced disability attorneys and staff members exclusively dedicated to assisting clients with their SSD and Supplemental Security Income cases throughout all 50 states and Puerto Rico.

Share article on social media or email:

health and fitness

Precision Botanical Launches the Purest CBD Brand Available That is Tested for Over 400 Contaminants Setting New Standards for All CBD Products

Leave a comment


https://www.prweb.com/

Precision Botanical is the most rigorously tested brand in the CBD industry with each batch tested for more than 400 contaminants.


DENVER (PRWEB)

A new CBD brand that launched today seeks to disrupt the industry with its products’ transparency, purity, label accuracy and superiority. Colorado-based Precision Botanical enters the market as the only “Science First” CBD brand that was created by a team of U.S.-based neuroscientists, chemists and toxicologists. Precision Botanical products come from its own Oregon hemp farm and uses a commercial-level proprietary extraction of hemp oil that’s in the patent process. All products are third-party audited and certified for potency and purity.

Approximately 45% of the top 10 CBD brands’ products contain THC and third-party testing reveals that the top selling products are on average tested for fewer than 20 contaminants. In comparison, Precision Botanical tests all of its source material as well as finished products for more than 400 contaminants. This ensures Precision Botanical products are 99% pure, with accurate concentrations in each product and all are made with pharmaceutical-level precision. All of its products carry Clean Label Project Purity and THC-Free Certification.

Precision Botanical CBD products include its Soothe line. These topicals provide mess-free application and each one easily fits into a daily regimen. They contain functional, natural ingredients and were created for athletes by athletes. The Soothe line features:


  • Soothe Roll-on (MSRP $24.99 for 10 ml)

  • Soothe Salve (MSRP $44.99 for 1 oz)

  • Soothe Salve with Menthol (MSRP $44.99 for 1 oz)

Other product lines offered by Precision Botanical include its Calm, Renew, Alert and Sleep lines:

  • Renew Face Cream (MSRP $44.99 for 1 oz)

  • Renew Eye Cream (MSRP $ 44.99 for 1 oz)

  • Calm Tincture (MSRP $44.99 for 750mg, MSRP $19.99 for 300mg)

  • Calm Capsules (MSRP $44.99 for 30-count; MSRP $7.99 for 4-count)

  • Sleep Capsules (MSRP $54.99 for 60-count)

  • Gummies (MSRP $9.99 for 6 count; MSRP $19.99 for 20-count)

  • Alert Shot (MSRP $7.99 for 2oz)

  • Alert Capsules (MSRP 7.99 for 4-count)

Visit https://precisionbotanical.com/ to purchase all Precision Botanical products or to learn more.

About Precision Botanical

Denver, Colorado-based Precision Botanical is committed to quality, purity and transparency in creating the best CBD products available anywhere. It’s the only “Science First” CBD brand on the market founded by a team of neuroscientists, chemists and toxicologists. It also is the most rigorously tested brand in the CBD industry with each batch tested for more than 400 contaminants. All product comes from its 100-acre farm in the U.S. and both source materials and finished products are continually tested for purity and accuracy, providing consumers with the peace of mind they deserve.

Share article on social media or email:

Industry: Healthcare

Access Healthcare Appoints Jessica Cooley as Chief Marketing Officer

Leave a comment


Jessica Cooley, Chief Marketing Officer, Access Healthcare

Jessica Cooley, CMO, Access Healthcare

The critical part of my responsibility is to identify the untapped potential to narrate our success story and demonstrate what truly differentiates Access Healthcare to our providers and RCM companies in the marketplace.


DALLAS (PRWEB)

Access Healthcare, one of the largest providers of healthcare revenue cycle management and IT services, today announced that Jessica Cooley has been appointed to the company’s executive leadership team as Chief Marketing Officer. In her new role, Cooley will spearhead the company’s global branding and marketing initiatives enabling the customer-facing sales efforts and building the teams towards executing the company’s strategic vision.

Cooley brings more than 17 years of experience in the healthcare industry and has a track record of generating significant profit, enhancing corporate credibility, and increasing market penetration. Prior to Access Healthcare, she was the Vice President of Strategic Accounts & Implementation for Provista, a Vizient subsidiary. While at Provista, she created and led the organization’s Strategic Accounts business unit, which now operates over $91 million in revenue responsibility. Cooley was instrumental in the ambulatory strategy development and execution as part of Provista’s long term growth plan. Cooley has earned several honors including President’s Circle 2016, Sales Excellence 2010, and Exceeding Excellence for 2003 and 2008.

“We are happy to welcome Jessica to our executive leadership team. Over the last few months, we’ve been focusing on building a strategy for how sales and marketing functions to enable the next phase of company’s growth,” says David Tassoni, President of US Operations of Access Healthcare. “We have been growing exponentially and Jessica’s deep marketing experience and strong business insights will bring significant opportunities for Access Healthcare and our business teams as we continue to move forward.”

“Access Healthcare is one of those brands that is revolutionizing the healthcare industry, and I’m truly excited to be part of this growing company,” says Cooley. “The critical part of my responsibility is to identify the untapped potential to narrate our success story and demonstrate what truly differentiates Access Healthcare to our providers and RCM companies in the marketplace.”

Cooley holds a B.S. in Human Development from Texas Tech University and is an active member of organizations such as the Young Men’s Service League, Professional Women in Healthcare, and the National Charity League.

About Access Healthcare

Access Healthcare provides business process outsourcing, applications services, and robotic process automation tools to healthcare providers, payers, and related service providers. The company operates from 19 delivery centers in the US, India and the Philippines, and its 12,000+ staff is committed to delivering revenue cycle excellence by leveraging technology, emerging best practices, and global delivery. Based in Dallas, Access Healthcare supports over 300,000 physicians, serves 80+ specialties, processes over $70 billion of A/R annually, and ascribes medical codes to over 30 million charts annually. To learn more, please visit http://www.accesshealthcare.com.

Share article on social media or email:

Press Release News Wire Service